Mailing of the Meeting materials has commenced, and Quorum Shareholders should receive them in due course. All of the Meeting materials can be accessed on Quorum’s corporate website ( ...

Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US and ...

Johnson & Johnson has kicked off a marketing application in the US for TAR-200 as a treatment for a form of bladder cancer, using a novel technology that releases the drug intravesically, or directly ...